If you had bought Novavax's (NASDAQ: NVAX) shares at the beginning of 2020, you'd be sitting on solid gains. The stock skyrocketed soon after the pandemic started as Novavax raced to develop a vaccine for the novel coronavirus. Even though it has given up most of these gains, it remains well in the green for those who got in early enough.
But it was impossible to predict Novavax's success at the time. Other smaller biotechs that tried to make waves in this market failed and have now become irrelevant. As for whether Novavax is still worth owning, we have much more data. Let's look at what's going on with Novavax to figure that out.
Source Fool.com